Edition:
India

Teva Announces Update On Fremanezumab Clinical Development For Use In Episodic Cluster Headache


Tuesday, 23 Apr 2019 

April 23 (Reuters) - Teva Pharmaceutical Industries Ltd ::TEVA ANNOUNCES UPDATE ON FREMANEZUMAB CLINICAL DEVELOPMENT FOR USE IN EPISODIC CLUSTER HEADACHE.TEVA PHARMACEUTICAL - PROVIDED AN UPDATE THAT COMPANY IS DISCONTINUING CLINICAL DEVELOPMENT PROGRAM FOR USE OF FREMANEZUMAB IN CLUSTER HEADACHES.TEVA PHARMACEUTICAL INDUSTRIES LTD - DISCONTINUING ENFORCE PHASE III CLINICAL TRIAL PROGRAM.TEVA PHARMACEUTICAL INDUSTRIES LTD - CONTINUES TO EXPLORE OTHER USES FOR FREMANEZUMAB, INCLUDING TREATMENT OF POST-TRAUMATIC HEADACHE.TEVA PHARMA - STUDY'S PRIMARY ENDPOINT IS UNLIKELY TO BE MET.